Pharmaceutical companies Novartis, Amgen, and Eli Lilly are investing in research to develop heart drugs targeting a specific form of bad cholesterol. This could lead to the next major cardiology blockbusters. The focus is on reducing levels of this harmful cholesterol.
Impact: The potential development of these heart drugs could significantly impact the pharmaceutical industry and related stocks.
Not investment advice